Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| UNITED THERAPEUTICS CorpUTHR · Entity 664 | EVP & GENERAL COUNSEL | October 01, 2026 | October 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
UNITED THERAPEUTICS Corp
Report date October 01, 2026 · Filed October 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 45,172 |
Ending reported balance
After 2026-10-01 transaction · row 11
11 source rows · reconciled sequenceRow 1 · 2026-10-01 · Exercise / conversion · Acquired 8,300 · Balance 53,472 F1: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025. Row 2 · 2026-10-01 · Sale · Disposed 880 · Balance 52,592 F1: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025. F2: This transaction was executed in multiple trades at prices ranging from $558.30 to $558.31. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 3 · 2026-10-01 · Sale · Disposed 1,480 · Balance 51,112 F1: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025. F3: This transaction was executed in multiple trades at prices ranging from $560.00 to $560.50. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 4 · 2026-10-01 · Sale · Disposed 780 · Balance 50,332 F1: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025. F4: This transaction was executed in multiple trades at prices ranging from $561.70 to $562.27. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 5 · 2026-10-01 · Sale · Disposed 1,480 · Balance 48,852 F1: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025. F5: This transaction was executed in multiple trades at prices ranging from $562.80 to $563.43. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 6 · 2026-10-01 · Sale · Disposed 400 · Balance 48,452 F1: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025. F6: This transaction was executed in multiple trades at prices ranging from $566.405 to $566.41. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 7 · 2026-10-01 · Sale · Disposed 720 · Balance 47,732 F1: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025. F7: This transaction was executed in multiple trades at prices ranging from $567.495 to $568.175. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 8 · 2026-10-01 · Sale · Disposed 739 · Balance 46,993 F1: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025. F8: This transaction was executed in multiple trades at prices ranging from $568.94 to $569.79. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 9 · 2026-10-01 · Sale · Disposed 838 · Balance 46,155 F1: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025. F9: This transaction was executed in multiple trades at prices ranging from $570.405 to $571.32. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 10 · 2026-10-01 · Sale · Disposed 823 · Balance 45,332 F1: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025. F10: This transaction was executed in multiple trades at prices ranging from $571.48 to $572.45. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 11 · 2026-10-01 · Sale · Disposed 160 · Balance 45,172 F1: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $146.03 · Expires 2027-03-15 | Direct | 39,240 |
Reported balance
After 2026-10-01 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2026-10-01 · Exercise / conversion · Disposed 8,300 · Balance 39,240 F1: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025.
F2: This transaction was executed in multiple trades at prices ranging from $558.30 to $558.31. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3: This transaction was executed in multiple trades at prices ranging from $560.00 to $560.50. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F4: This transaction was executed in multiple trades at prices ranging from $561.70 to $562.27. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F5: This transaction was executed in multiple trades at prices ranging from $562.80 to $563.43. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F6: This transaction was executed in multiple trades at prices ranging from $566.405 to $566.41. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F7: This transaction was executed in multiple trades at prices ranging from $567.495 to $568.175. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F8: This transaction was executed in multiple trades at prices ranging from $568.94 to $569.79. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F9: This transaction was executed in multiple trades at prices ranging from $570.405 to $571.32. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F10: This transaction was executed in multiple trades at prices ranging from $571.48 to $572.45. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 15, 2025 Filed May 20, 2025 20:32 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 2 | $302.02 | $604.04 |
DisclosureSEC source: 0001562180-25-004035 · primarydocument.xml · nonDerivative · entry 9 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,781 F1 · kind: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on December 24, 2024. Read SEC document |
| May 15, 2025 Filed May 20, 2025 20:32 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 203 | $300.24 | $60,948.15 |
DisclosureSEC source: 0001562180-25-004035 · primarydocument.xml · nonDerivative · entry 8 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,783 F1 · kind: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on December 24, 2024. F7 · price: This transaction was executed in multiple trades at prices ranging from $300.20 to $300.98. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 15, 2025 Filed May 20, 2025 20:32 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 4 | $299.00 | $1,196.00 |
DisclosureSEC source: 0001562180-25-004035 · primarydocument.xml · nonDerivative · entry 7 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,986 F1 · kind: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on December 24, 2024. Read SEC document |
| May 15, 2025 Filed May 20, 2025 20:32 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 800 | $297.33 | $237,866.00 |
DisclosureSEC source: 0001562180-25-004035 · primarydocument.xml · nonDerivative · entry 6 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,990 F1 · kind: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on December 24, 2024. F6 · price: This transaction was executed in multiple trades at prices ranging from $297.09 to $298.01. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 15, 2025 Filed May 20, 2025 20:32 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,744 | $296.41 | $516,930.32 |
DisclosureSEC source: 0001562180-25-004035 · primarydocument.xml · nonDerivative · entry 5 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,790 F1 · kind: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on December 24, 2024. F5 · price: This transaction was executed in multiple trades at prices ranging from $295.85 to $296.84. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 15, 2025 Filed May 20, 2025 20:32 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 5,004 | $295.10 | $1,476,679.90 |
DisclosureSEC source: 0001562180-25-004035 · primarydocument.xml · nonDerivative · entry 4 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 39,534 F1 · kind: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on December 24, 2024. F4 · price: This transaction was executed in multiple trades at prices ranging from $294.77 to $295.61. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 15, 2025 Filed May 20, 2025 20:32 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,104 | $293.96 | $324,526.43 |
DisclosureSEC source: 0001562180-25-004035 · primarydocument.xml · nonDerivative · entry 3 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,538 F1 · kind: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on December 24, 2024. F3 · price: This transaction was executed in multiple trades at prices ranging from $293.67 to $294.51. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 15, 2025 Filed May 20, 2025 20:32 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 2,139 | $293.31 | $627,399.07 |
DisclosureSEC source: 0001562180-25-004035 · primarydocument.xml · nonDerivative · entry 2 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 45,642 F1 · kind: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on December 24, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $292.615 to $293.61. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 15, 2025 Filed May 20, 2025 20:32 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 11,000 | $117.76 | $1,295,360.00 |
DisclosureSEC source: 0001562180-25-004035 · primarydocument.xml · nonDerivative · entry 1 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 47,781 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on December 24, 2024. Read SEC document |
| May 01, 2025 Filed May 2, 2025 20:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Option · Derivative | 11,000 | $0.00 Strike: $117.76 | $0.00 |
DisclosureSEC source: 0001562180-25-003491 · primarydocument.xml · derivative · entry 11 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 11,000 shares Expires 2027-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on December 24, 2024. Read SEC document |
| May 01, 2025 Filed May 2, 2025 20:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 120 | $303.38 | $36,405.60 |
DisclosureSEC source: 0001562180-25-003491 · primarydocument.xml · nonDerivative · entry 10 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,781 F1 · kind: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on December 24, 2024. Read SEC document |
| May 01, 2025 Filed May 2, 2025 20:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 3,859 | $302.71 | $1,168,140.91 |
DisclosureSEC source: 0001562180-25-003491 · primarydocument.xml · nonDerivative · entry 9 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,901 F1 · kind: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on December 24, 2024. F9 · price: This transaction was executed in multiple trades at prices ranging from $302.34 to $303.215. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 01, 2025 Filed May 2, 2025 20:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 3,392 | $301.81 | $1,023,747.32 |
DisclosureSEC source: 0001562180-25-003491 · primarydocument.xml · nonDerivative · entry 8 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 40,760 F1 · kind: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on December 24, 2024. F8 · price: This transaction was executed in multiple trades at prices ranging from $301.335 to $302.315. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 01, 2025 Filed May 2, 2025 20:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,320 | $300.63 | $396,830.15 |
DisclosureSEC source: 0001562180-25-003491 · primarydocument.xml · nonDerivative · entry 7 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,152 F1 · kind: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on December 24, 2024. F7 · price: This transaction was executed in multiple trades at prices ranging from $300.23 to $301.10. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 01, 2025 Filed May 2, 2025 20:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 500 | $299.05 | $149,524.50 |
DisclosureSEC source: 0001562180-25-003491 · primarydocument.xml · nonDerivative · entry 6 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 45,472 F1 · kind: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on December 24, 2024. F6 · price: This transaction was executed in multiple trades at prices ranging from $298.975 to $299.19. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 01, 2025 Filed May 2, 2025 20:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 300 | $298.05 | $89,415.51 |
DisclosureSEC source: 0001562180-25-003491 · primarydocument.xml · nonDerivative · entry 5 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 45,972 F1 · kind: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on December 24, 2024. F5 · price: This transaction was executed in multiple trades at prices ranging from $297.915 to $298.12. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 01, 2025 Filed May 2, 2025 20:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 239 | $297.00 | $70,983.10 |
DisclosureSEC source: 0001562180-25-003491 · primarydocument.xml · nonDerivative · entry 4 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 46,272 F1 · kind: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on December 24, 2024. F4 · price: This transaction was executed in multiple trades at prices ranging from $296.855 to $297.105. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 01, 2025 Filed May 2, 2025 20:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 400 | $296.00 | $118,399.48 |
DisclosureSEC source: 0001562180-25-003491 · primarydocument.xml · nonDerivative · entry 3 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 46,511 F1 · kind: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on December 24, 2024. F3 · price: This transaction was executed in multiple trades at prices ranging from $295.76 to $296.715. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 01, 2025 Filed May 2, 2025 20:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 870 | $295.12 | $256,754.92 |
DisclosureSEC source: 0001562180-25-003491 · primarydocument.xml · nonDerivative · entry 2 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 46,911 F1 · kind: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on December 24, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $294.71 to $295.6225. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 01, 2025 Filed May 2, 2025 20:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 11,000 | $117.76 | $1,295,360.00 |
DisclosureSEC source: 0001562180-25-003491 · primarydocument.xml · nonDerivative · entry 1 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 47,781 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on December 24, 2024. Read SEC document |
| April 17, 2025 Filed Apr 18, 2025 20:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Option · Derivative | 11,000 | $0.00 Strike: $117.76 | $0.00 |
DisclosureSEC source: 0001562180-25-003212 · primarydocument.xml · derivative · entry 6 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,000 Underlying: Common Stock · 11,000 shares Expires 2027-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on December 24, 2024. Read SEC document |
| April 17, 2025 Filed Apr 18, 2025 20:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 3,096 | $284.69 | $881,396.22 |
DisclosureSEC source: 0001562180-25-003212 · primarydocument.xml · nonDerivative · entry 5 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,781 F1 · kind: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on December 24, 2024. F5 · price: This transaction was executed in multiple trades at prices ranging from $284.38 to $285.07. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 17, 2025 Filed Apr 18, 2025 20:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 5,488 | $283.83 | $1,557,634.89 |
DisclosureSEC source: 0001562180-25-003212 · primarydocument.xml · nonDerivative · entry 4 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 39,877 F1 · kind: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on December 24, 2024. F4 · price: This transaction was executed in multiple trades at prices ranging from $283.37 to $284.35. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 17, 2025 Filed Apr 18, 2025 20:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 2,016 | $282.92 | $570,370.95 |
DisclosureSEC source: 0001562180-25-003212 · primarydocument.xml · nonDerivative · entry 3 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 45,365 F1 · kind: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on December 24, 2024. F3 · price: This transaction was executed in multiple trades at prices ranging from $282.36 to $283.325. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 17, 2025 Filed Apr 18, 2025 20:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 400 | $280.35 | $112,141.00 |
DisclosureSEC source: 0001562180-25-003212 · primarydocument.xml · nonDerivative · entry 2 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 47,381 F1 · kind: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on December 24, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $279.95 to $280.66. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 17, 2025 Filed Apr 18, 2025 20:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 11,000 | $117.76 | $1,295,360.00 |
DisclosureSEC source: 0001562180-25-003212 · primarydocument.xml · nonDerivative · entry 1 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 47,781 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on December 24, 2024. Read SEC document |
| April 03, 2025 Filed Apr 7, 2025 13:05 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Option · Derivative | 11,000 | $0.00 Strike: $117.76 | $0.00 |
DisclosureSEC source: 0001562180-25-003030 · primarydocument.xml · derivative · entry 8 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,000 Underlying: Common Stock · 11,000 shares Expires 2027-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on December 24, 2024. Read SEC document |
| April 03, 2025 Filed Apr 7, 2025 13:05 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,501 | $308.08 | $462,429.73 |
DisclosureSEC source: 0001562180-25-003030 · primarydocument.xml · nonDerivative · entry 7 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,781 F1 · kind: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on December 24, 2024. F5 · price: This transaction was executed in multiple trades at prices ranging from $307.685 to $308.54. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 03, 2025 Filed Apr 7, 2025 13:05 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 3,787 | $307.12 | $1,163,054.35 |
DisclosureSEC source: 0001562180-25-003030 · primarydocument.xml · nonDerivative · entry 6 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 38,282 F1 · kind: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on December 24, 2024. F4 · price: This transaction was executed in multiple trades at prices ranging from $306.67 to $307.65. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 03, 2025 Filed Apr 7, 2025 13:05 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 2,218 | $306.08 | $678,888.99 |
DisclosureSEC source: 0001562180-25-003030 · primarydocument.xml · nonDerivative · entry 5 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 42,069 F1 · kind: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on December 24, 2024. F3 · price: This transaction was executed in multiple trades at prices ranging from $305.64 to $306.62. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 03, 2025 Filed Apr 7, 2025 13:05 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 3,094 | $305.08 | $943,927.73 |
DisclosureSEC source: 0001562180-25-003030 · primarydocument.xml · nonDerivative · entry 4 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,287 F1 · kind: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on December 24, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $304.64 to $305.63. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 03, 2025 Filed Apr 7, 2025 13:05 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 200 | $300.42 | $60,083.00 |
DisclosureSEC source: 0001562180-25-003030 · primarydocument.xml · nonDerivative · entry 3 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 47,381 F1 · kind: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on December 24, 2024. Read SEC document |
| April 03, 2025 Filed Apr 7, 2025 13:05 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 200 | $298.00 | $59,600.00 |
DisclosureSEC source: 0001562180-25-003030 · primarydocument.xml · nonDerivative · entry 2 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 47,581 F1 · kind: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on December 24, 2024. Read SEC document |
| April 03, 2025 Filed Apr 7, 2025 13:05 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 11,000 | $117.76 | $1,295,360.00 |
DisclosureSEC source: 0001562180-25-003030 · primarydocument.xml · nonDerivative · entry 1 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 47,781 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on December 24, 2024. Read SEC document |
| March 06, 2025 Filed Mar 7, 2025 21:33 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionShare Tracking Award · Derivative | 6,550 | $0.00 Strike: $163.30 | $0.00 |
DisclosureSEC source: 0001562180-25-002202 · primarydocument.xml · derivative · entry 3 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,550 shares Expires 2025-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. F1 · kind: This is an exercise of share tracking awards pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on June 20, 2024. Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. Read SEC document |
| March 06, 2025 Filed Mar 7, 2025 21:33 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Disposition to issuerCommon Stock | 6,550 | $307.68 | $2,015,304.00 |
DisclosureSEC source: 0001562180-25-002202 · primarydocument.xml · nonDerivative · entry 2 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,781 F1 · kind: This is an exercise of share tracking awards pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on June 20, 2024. Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. F2 · balance_after: Includes 71 shares of common stock acquired on March 4, 2025 under the United Therapeutics Employee Stock Purchase Plan. Read SEC document |
| March 06, 2025 Filed Mar 7, 2025 21:33 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 6,550 | $163.30 | $1,069,615.00 |
DisclosureSEC source: 0001562180-25-002202 · primarydocument.xml · nonDerivative · entry 1 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 43,331 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This is an exercise of share tracking awards pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on June 20, 2024. Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. F2 · balance_after: Includes 71 shares of common stock acquired on March 4, 2025 under the United Therapeutics Employee Stock Purchase Plan. Read SEC document |
| February 20, 2025 Filed Feb 21, 2025 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionShare Tracking Award · Derivative | 7,700 | $0.00 Strike: $163.30 | $0.00 |
DisclosureSEC source: 0001562180-25-001496 · primarydocument.xml · derivative · entry 3 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,550 Underlying: Common Stock · 7,700 shares Expires 2025-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. F1 · kind: This is an exercise of share tracking awards pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on June 20, 2024. Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. Read SEC document |
| February 20, 2025 Filed Feb 21, 2025 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Disposition to issuerCommon Stock | 7,700 | $367.36 | $2,828,672.00 |
DisclosureSEC source: 0001562180-25-001496 · primarydocument.xml · nonDerivative · entry 2 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,710 F1 · kind: This is an exercise of share tracking awards pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on June 20, 2024. Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. Read SEC document |
| February 20, 2025 Filed Feb 21, 2025 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 7,700 | $163.30 | $1,257,410.00 |
DisclosureSEC source: 0001562180-25-001496 · primarydocument.xml · nonDerivative · entry 1 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,410 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This is an exercise of share tracking awards pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on June 20, 2024. Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. Read SEC document |
| February 06, 2025 Filed Feb 10, 2025 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionShare Tracking Award · Derivative | 7,700 | $0.00 Strike: $163.30 | $0.00 |
DisclosureSEC source: 0001562180-25-001057 · primarydocument.xml · derivative · entry 3 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,250 Underlying: Common Stock · 7,700 shares Expires 2025-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. F1 · kind: This is an exercise of share tracking awards pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on June 20, 2024. Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. Read SEC document |
| February 06, 2025 Filed Feb 10, 2025 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Disposition to issuerCommon Stock | 7,700 | $353.75 | $2,723,875.00 |
DisclosureSEC source: 0001562180-25-001057 · primarydocument.xml · nonDerivative · entry 2 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,710 F1 · kind: This is an exercise of share tracking awards pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on June 20, 2024. Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. Read SEC document |
| February 06, 2025 Filed Feb 10, 2025 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 7,700 | $163.30 | $1,257,410.00 |
DisclosureSEC source: 0001562180-25-001057 · primarydocument.xml · nonDerivative · entry 1 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,410 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This is an exercise of share tracking awards pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on June 20, 2024. Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. Read SEC document |
| January 16, 2025 Filed Jan 17, 2025 21:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionShare Tracking Award · Derivative | 7,700 | $0.00 Strike: $163.30 | $0.00 |
DisclosureSEC source: 0001562180-25-000401 · primarydocument.xml · derivative · entry 3 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,950 Underlying: Common Stock · 7,700 shares Expires 2025-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. F1 · kind: This is an exercise of share tracking awards pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on June 20, 2024. Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. Read SEC document |
| January 16, 2025 Filed Jan 17, 2025 21:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Disposition to issuerCommon Stock | 7,700 | $366.39 | $2,821,203.00 |
DisclosureSEC source: 0001562180-25-000401 · primarydocument.xml · nonDerivative · entry 2 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,710 F1 · kind: This is an exercise of share tracking awards pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on June 20, 2024. Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. Read SEC document |
| January 16, 2025 Filed Jan 17, 2025 21:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 7,700 | $163.30 | $1,257,410.00 |
DisclosureSEC source: 0001562180-25-000401 · primarydocument.xml · nonDerivative · entry 1 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,410 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This is an exercise of share tracking awards pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on June 20, 2024. Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. Read SEC document |
| January 02, 2025 Filed Jan 3, 2025 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionShare Tracking Award · Derivative | 7,700 | $0.00 Strike: $163.30 | $0.00 |
DisclosureSEC source: 0001562180-25-000111 · primarydocument.xml · derivative · entry 3 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,650 Underlying: Common Stock · 7,700 shares Expires 2025-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. F1 · kind: This is an exercise of share tracking awards pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on June 20, 2024. Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. Read SEC document |
| January 02, 2025 Filed Jan 3, 2025 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Disposition to issuerCommon Stock | 7,700 | $360.22 | $2,773,694.00 |
DisclosureSEC source: 0001562180-25-000111 · primarydocument.xml · nonDerivative · entry 2 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,710 F1 · kind: This is an exercise of share tracking awards pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on June 20, 2024. Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. Read SEC document |
| January 02, 2025 Filed Jan 3, 2025 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 7,700 | $163.30 | $1,257,410.00 |
DisclosureSEC source: 0001562180-25-000111 · primarydocument.xml · nonDerivative · entry 1 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,410 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This is an exercise of share tracking awards pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on June 20, 2024. Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. Read SEC document |
| December 19, 2024 Filed Dec 20, 2024 21:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionShare Tracking Award · Derivative | 7,700 | $0.00 Strike: $163.30 | $0.00 |
DisclosureSEC source: 0001562180-24-008538 · primarydocument.xml · derivative · entry 3 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,350 Underlying: Common Stock · 7,700 shares Expires 2025-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. F1 · kind: This is an exercise of share tracking awards pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on June 20, 2024. Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.